Ecstatic Phenomena in Epilepsy Surgery: Neural Localization Insights

Systematic Review Pinpoints Brain Regions for Ecstatic Phenomena in Epilepsy

A September 2026 systematic review (OpenAlex W7213460228) synthesizes evidence from clinical and surgical studies to localize the brain regions responsible for ecstatic or mystical experiences during focal epilepsy. The review, which analyzed 33 studies and focused on 9 high-confidence surgical cases, finds that the temporal lobe—especially its anterior, basal, and mesial regions—serves as the primary epileptogenic zone (EZ) for these phenomena. In contrast, the insular cortex, particularly the dorsal anterior insula, emerges as the most consistent symptomatogenic zone (SZ) based on direct electrical stimulation and intracranial recordings.

This distinction between the EZ and SZ is crucial: while the EZ is the site where seizures originate, the SZ is where the subjective ecstatic aura is generated. The review's rigorous approach—applying strict criteria for anatomical confidence—lends weight to these findings, despite the limited sample size.

Mechanisms and Context: Implications for Altered States Research

The identification of the insular and temporal lobes as neural correlates of ecstatic experiences in epilepsy provides a concrete anatomical framework for understanding altered states of consciousness. These findings are highly relevant for researchers investigating the neural basis of psychedelic-induced mystical states, as both domains involve profound changes in self-perception, time experience, and emotional valence.

Notably, the insular cortex has been implicated in interoceptive awareness and emotional integration, while the temporal lobe is central to autobiographical memory and semantic processing. The review's localization of ecstatic auras to the dorsal anterior insula aligns with recent neuroimaging studies of psychedelic states, which report altered insular activity during peak experiences. This convergence suggests a shared neural substrate for both pathological (epileptic) and pharmacologically induced (psychedelic) mystical phenomena.

One non-obvious implication is that surgical interventions targeting these regions in epilepsy may inadvertently alter a patient's propensity for altered states, raising important questions for both clinical and ethical management.

Policy and Research Implications for Psychedelic Science

These findings have several implications for policy makers, clinical researchers, and translational scientists working in psychedelic medicine. First, the review underscores the need for precise neuroanatomical mapping in both epilepsy surgery and psychedelic research. Understanding the distinct roles of the insula and temporal lobe could inform the design of neuroimaging protocols, neuromodulation studies, and even the development of targeted interventions for treatment-resistant conditions.

For regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), this evidence base supports the rationale for integrating advanced neuroimaging and electrophysiological endpoints in clinical trials of psychedelic compounds. It also highlights the value of cross-disciplinary research, bridging epilepsy surgery and psychedelic neuroscience, to refine models of consciousness and therapeutic mechanisms.

Importantly, the review's methodology—prioritizing high-confidence anatomical data—sets a standard for future systematic reviews in both fields. However, the limited sample size and high risk of bias in the existing literature point to a critical need for multi-center registries and prospective studies with harmonized protocols.

Risks, Limitations, and Unknowns

The principal limitation of the review is the small number of high-quality cases—only 9 patients met stringent inclusion criteria for definitive localization. This reflects broader challenges in the field, including heterogeneity in reporting, variability in surgical mapping techniques, and the rarity of ecstatic auras in epilepsy cohorts. The high risk of bias in many included studies further tempers the generalizability of the findings.

For the psychedelic research community, extrapolating from pathological states (epilepsy) to pharmacologically induced states (psychedelics) is inherently fraught. While the overlap in neural substrates is compelling, differences in network dynamics, neurochemical context, and subjective experience must be acknowledged. There is also a risk that overemphasizing single-region localization may obscure the distributed, network-based nature of altered states.

A concrete failure mode not widely discussed is the possibility that surgical ablation or stimulation of these regions could lead to unintended changes in affective or cognitive processing—either blunting or exacerbating susceptibility to altered states. This underscores the importance of longitudinal follow-up and patient-centered outcome measures in both epilepsy and psychedelic research.

Looking Forward: Bridging Epilepsy and Psychedelic Neuroscience

Future research should prioritize larger, prospective studies with standardized neuroimaging and electrophysiological protocols to validate and extend these findings. Collaborative efforts between epilepsy centers and psychedelic research groups could accelerate the development of robust biomarkers for altered states of consciousness.

For clinicians and policy makers, the review highlights the need for nuanced risk-benefit assessments when considering interventions targeting the insular and temporal lobes. For the psychedelic field, these insights offer a roadmap for hypothesis-driven studies and a cautionary note on the complexities of neural localization.

As the boundaries between clinical neurology and psychedelic science continue to blur, rigorous, cross-disciplinary research will be essential to translate mechanistic insights into safe and effective interventions for patients.

How we research: Reviewed by Dr. Alex M. Hart, MD, PhD (Board-certified Neurologist and Clinical Researcher) on 2026-09-20. Primary sources: OpenAlex W7213460228; PubMed; FDA neuroimaging guidance.